h.dumitru96/100
Release signed and dated, named individual. Vial-to-vial mass variation under 2%. Evidence base adequate for a rating on this criterion.
Homopeptide — Hunan Aslsen Technology Co., Ltd.
Changsha, CN. The index holds 457 assay reports across 71 batches and 32 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where Homopeptide sells
Hunan Aslsen Technology Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit Homopeptide at homopeptide.net →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Hunan Aslsen Technology Co., Ltd.
- Short code in this index
- Homopeptide
- Also known as
- Homopeptide · Homopeptide Bio · Aslsen
- Domain
- homopeptide.net →
- City
- Changsha
- Region
- Hunan
- Country
- CN
- Established
- not stated
- First record in index
- 09 Jan 2024
- Most recent record
- 15 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
16.2%
n=457
Retail, shipped to the buyer
75.1%
n=457
Direct to the laboratory
3.7%
n=457
Median courier leg, direct despatch
8d
n=17
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 74 | 16.2% |
| Retail purchase, shipped to the buyer | 283 | 61.9% |
| Retail purchase via a third-party forwarder | 60 | 13.1% |
| Supplier despatch direct to the laboratory | 17 | 3.7% |
| Laboratory retained-sample archive | 23 | 5.0% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 457 Homopeptide records the index holds, 74 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 23 of the 32 compounds Homopeptide is represented by here — Semaglutide, Retatrutide, GHK-Cu, Semax, Glucagon, L-Glutathione (reduced) and 17 further compounds. Those are the Homopeptide lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
No contributor to this index has named a regional stock location for Homopeptide. 74 of its records nevertheless arrived by a domestic-warehouse route, so stock is held somewhere; the index does not know where and will not guess.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is Homopeptide's own reviewers: 2 of the 26 on-record reviews state a quoted window and what happened against it. Where Homopeptide despatched a sample direct to a laboratory, the courier leg ran a median 8 days across 17 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.32%
n=457
Interquartile range
0.85pp
n=457
10th percentile
98.35%
n=457
Pass rate vs index spec
99.6%
n=457
Median recovery vs claim
97.0%
n=257
Median water
5.33%
n=457
Median |mass error|
2.1ppm
n=379
Records carrying a flag
24.1%
n=457
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.59pp
n=51
Index median spread
0.67pp
n=28
Lots tested 3+ times
51
n=71
Across the 51 Homopeptide lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.59 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
0.00pp
n=71
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
49%
n=71
Divergences beyond 1 pp
0%
n=71
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
99.32%
n=417
Supplier-supplied median
99.60%
n=17
Supplier-supplied share of records
3.7%
n=457
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of Homopeptide batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
85/100
n=71
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 65% | 25 points | |
| Peptide content stated | 54% | 20 points | |
| Endotoxin stated | 39% | 15 points | |
| Named impurities rather than a total | 57% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Semaglutide | Incretin | 90 | 98.98 | 98.89 | +0.09 | 97.0 | 100 |
| Retatrutide | Incretin | 64 | 98.68 | 98.37 | +0.31 | 96.5 | 100 |
| Semax | Neuroactive | 30 | 99.67 | 99.46 | +0.22 | 98.5 | 100 |
| Tirzepatide | Incretin | 21 | 98.58 | 98.55 | +0.03 | 97.0 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 19 | 99.93 | 99.49 | +0.44 | 98.5 | 100 |
| ARA-290 | Tissue-repair | 18 | 99.56 | 99.42 | +0.14 | 98.0 | 100 |
| SS-31 (Elamipretide) | Metabolic | 17 | 99.93 | 99.53 | +0.40 | 98.5 | 100 |
| N-Acetyl Semax Amide | Neuroactive | 17 | 99.17 | 99.35 | -0.18 | 98.5 | 100 |
| L-Glutathione (reduced) | Short | 15 | 99.73 | 99.33 | +0.40 | 98.5 | 100 |
| TB-500 | Tissue-repair | 15 | 99.43 | 99.53 | -0.10 | 98.5 | 100 |
| IGF-1 LR3 | Growth-hormone | 14 | 98.93 | 98.28 | +0.65 | 95.0 | 100 |
| Survodutide | Incretin | 14 | 99.35 | 98.38 | +0.97 | 96.5 | 100 |
| Oxytocin | Hypothalamic | 14 | 99.93 | 99.81 | +0.12 | 98.5 | 100 |
| KPV | Tissue-repair | 13 | 99.48 | 99.64 | -0.16 | 99.0 | 85 |
| GHK-Cu | Tissue-repair | 13 | 99.10 | 98.56 | +0.54 | 97.0 | 100 |
| Glucagon | Incretin | 12 | 99.22 | 99.20 | +0.02 | 98.0 | 100 |
| Leuprolide | Hypothalamic | 11 | 99.61 | 99.28 | +0.33 | 98.5 | 100 |
| GHRP-6 | Growth-hormone | 11 | 99.89 | 99.54 | +0.35 | 99.0 | 100 |
| Epitalon | Short | 10 | 99.93 | 99.56 | +0.37 | 99.0 | 100 |
| Melanotan II | Melanocortin-receptor | 6 n=6 | 99.20 | 99.42 | -0.22 | 98.5 | 100 |
| BPC-157 | Tissue-repair | 6 n=6 | 99.26 | 99.16 | +0.10 | 98.0 | 100 |
| L-Carnosine | Short | 6 n=6 | 99.66 | 99.58 | +0.08 | 99.0 | 100 |
| Selank | Neuroactive | 4 n=4 | 99.72 | 99.59 | +0.13 | 99.0 | 100 |
| LL-37 | Tissue-repair | 3 n=3 | 99.01 | 98.90 | +0.11 | 96.5 | 100 |
| Hexarelin | Growth-hormone | 3 n=3 | 99.66 | 99.59 | +0.07 | 99.0 | 100 |
| Ipamorelin | Growth-hormone | 2 n=2 | n<3 | 99.47 | — | 99.0 | 100 |
| GHRP-2 | Growth-hormone | 2 n=2 | n<3 | 99.28 | — | 99.0 | 100 |
| Afamelanotide | Melanocortin-receptor | 2 n=2 | n<3 | 99.06 | — | 98.0 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 2 n=2 | n<3 | 99.38 | — | 98.5 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 1 n=1 | n<3 | 99.09 | — | 98.0 | 100 |
| PEG-MGF | Growth-hormone | 1 n=1 | n<3 | 97.75 | — | 92.0 | 100 |
| Humanin (HNG) | Metabolic | 1 n=1 | n<3 | 99.12 | — | 97.5 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 2 | 14 | 99.44 | 99.21–99.70 | 1 |
| 2024-Q2 | 5 | 38 | 98.75 | 97.82–99.93 | 8 |
| 2024-Q3 | 7 | 48 | 99.28 | 97.83–99.93 | 9 |
| 2024-Q4 | 4 | 29 | 99.66 | 99.01–99.93 | 2 |
| 2025-Q1 | 9 | 44 | 99.52 | 98.75–99.93 | 12 |
| 2025-Q2 | 4 | 16 | 99.65 | 98.10–99.93 | 1 |
| 2025-Q3 | 5 | 47 | 98.47 | 97.24–99.75 | 21 |
| 2025-Q4 | 8 | 43 | 99.40 | 97.79–99.93 | 18 |
| 2026-Q1 | 12 | 74 | 99.30 | 98.56–99.93 | 25 |
| 2026-Q2 | 8 | 59 | 99.34 | 98.40–99.93 | 9 |
| 2026-Q3 | 7 | 45 | 99.23 | 98.29–99.93 | 4 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 220 | 99.32 | +0.00 | 99.32 |
| PeptideMeter | 75 | 99.20 | -0.05 | 99.25 |
| Medutest | 66 | 99.52 | +0.08 | 99.44 |
| VendorInvestigate | 39 | 99.21 | -0.11 | 99.32 |
| Nordanalyt | 34 | 99.13 | +0.02 | 99.11 |
| Kestrel | 23 | 99.87 | +0.24 | 99.63 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
95.0/ 100557 ratings across the index network
j.boateng95/100
Counter-ion identity and content answered quantitatively, one working day. Regional stock held for the lines concerned. Figures as reported by the named service. Not reproduced by the index.
h.ogunleye98/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Signature and release date present. Not medical advice.
ha.frisk97/100
Retention time assigned to the principal peak, printed. Nothing unsecured in the consignment.
f.duarte97/100
Consistency: 5 lots, purity band under 1.0 points wide. Documentation practice, not a single purity figure, is the substance here.
k.nyberg96/100
Supplementary certificate for a lot released 15 months earlier retrieved from supplier records on request. Medutest report held on file, figures match published.
b.kaufmann99/100
Declared figure not adjusted upward between certificate and commercial documentation. No further comment.
l.petrescu98/100
Certificate carries an assigned retention time for the main peak. Complete against the index minimum data set at first issue.
ra.vermeulen99/100
Custom synthesis delivered 3 days inside the quoted schedule at the specified purity. Record covers the lots named. Not generalised.
w.perrin98/100
Documentation complete at first issue. No supplementary request raised. Supplementary certificate produced without demur. Documentation practice, not a single purity figure, is the substance here.
l.boateng95/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Technical response inside four hours, working day. Further submissions on later lots would improve coverage.
co.grimaldi96/100
Water content by Karl Fischer, method named. Identity confirmed by two orthogonal methods. No further comment.
p.yildiz98/100
Labelling printed, lot and date legible on every unit examined. Peptide content 99.0%. Submitted to the index in full.
b.halvorsen99/100
Cold chain intact. Phase-change pack solid at arrival, day 5. Regional stock held for the lines concerned. Record covers the lots named. Not generalised.
s.hovland96/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Signature and release date present. Research use. Not approved for human administration.
ca.ramos97/100
11 orders, 10 months. No substitution, no reformulation, no post-payment unavailability. Nothing unsecured in the consignment.
tu.kaufmann99/100
Batch record supplied in full on request, attached rather than summarised. Technical response inside four hours, working day. Not medical advice.
s.ndiaye95/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. PeptideMeter report held on file, figures match published. Subsequent orders placed with the same supplier.
ka.castellanos100/100
Four orders, four lot-specific certificates issued against the lot code on the vial. Nothing needed chasing.
a.espinoza98/100
Reconstitution of kisspeptin-10 5 mg: clear on contact, no haze, no particulate. Bulk break points published rather than negotiated, and the invoice matched the published step. Further submissions on later lots would improve coverage.
l.ndiaye99/100
Fill uniformity: 7 units weighed against declared fill, all within 2%. No further comment.
e.salgado100/100
Certificate issued against the lot code printed on the vial, with the release signature and date on it. Submitted to the index in full.
a.salgado97/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. Technical response inside four hours, working day. Subsequent orders placed with the same supplier.
p.roos96/100
Peptide content reported separately from chromatographic purity across all 4 certificates held. Research use. Not approved for human administration.
r.solberg95/100
Direct-supply material 97.5%. Intermediary vial, same nominal description, 97.1%. Figures as reported by the named service. Not reproduced by the index.
e.demir99/100
Residual-solvent screen included unrequested. Quoted lead time from regional stock met to the day, and the price held for the quoted validity period. Not medical advice.
Block 12
Most recent records
Block 13
Contributor annotations on Homopeptide records 876
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on Homopeptide material are below, each linked to the record it sits on.
The reported figure derives from the plate count and the retention gap, via the pharmacopoeial form with the sum of both peak widths in the denominator. It is a calculated quantity, not a measured one, and it inherits the plate count's uncertainty.
Even a perfectly blind purchase is a lot somebody chose to test. Provenance fixes one selection problem and leaves the other standing.
One result at the top of the distribution should not move anybody's estimate much on its own. Purity distributions are compressed at the top and long-tailed at the bottom, so the informative observations are the low ones.
At 99.36 % the deletion-sequence family is at or below the reporting threshold. On a sequence with a hindered coupling that is a statement about coupling efficiency, and a good one.
A single result at 99.36 % is one draw. What makes a supplier's process legible is the spread across its lots, and that is on the scorecard rather than here. This record is one good point in a distribution worth reading whole.
Buyer-sourced through an ordinary retail order, so the supplier had no opportunity to select the vial. This is the provenance class the index weights and it is roughly 87 % of the dataset.
The certificate for HOMO-2604-D5484 carries a named related-substances table rather than a totals line. That is what makes 99.93 % checkable against this record instead of merely comparable to it.
A high figure on one vial is a statement about one vial. The within-lot spread on the batch rollup is what tells you whether the bulk was well mixed, and it is the rarer and more useful number.
Every annotation the index holds on Homopeptide material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what Homopeptide itself publishes, open homopeptide.net → alongside.
Block 14
Where to buy Homopeptide
Hunan Aslsen Technology Co., Ltd. sells direct from homopeptide.net. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the Homopeptide store at homopeptide.net →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.